Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 4—April 2024
Research Letter

Opportunistic Elizabethkingia miricola Infections in Intensive Care Unit, Spain

Eva Soler-IborteComments to Author , Mario Rivera-Izquierdo, and Carmen Valero-Ubierna
Author affiliations: Hospital Universitario San Cecilio, Granada, Spain (E. Soler-Iborte, M. Rivera-Izquierdo, C. Valero-Ubierna); Instituto biosanitario de Granada, Granada, (M. Rivera-Izquierdo); Ciber de Epidemiología y Salud Pública, Madrid, Spain (M. Rivera-Izquierdo)

Main Article

Table

Characteristics of case-patients in an outbreak opportunistic Elizabethkingia miricola infections in an intensive care unit, Spain*

Age, y/sex Isolation
sample		 ICU stay, d Diagnosis† Diagnosis date, 2021 Death Reason for admission Antimicrobial drug resistance‡
66/M
 BAS
 40
 Isolation
 Mar 17
 N
 COVID-19
 Carbapenems, ceftazidime, cefepime, aztreonam
70/M
 BAS
 63
 Isolation
 Mar 19
 N
 COVID-19
 Carbapenems, ceftazidime, cefepime, aztreonam
46/F
 BAS
 12
 Isolation
 Mar 27
 Y
 Carcinosis
 Carbapenems, ceftazidime, cefepime, aztreonam, aminoglycosides
64/M
 BAS
 61
 Tracheobronchitis
 Apr 22
 N
 COVID-19
 Carbapenems, ceftazidime, cefepime, aztreonam, piperacillin/tazobactam
57/F
 BAS, catheter
 20
 Bacteriemia
 Apr 27
 Y
 COVID-19
 Carbapenems, ceftazidime, cefepime, aztreonam, piperacillin/tazobactam, aminoglycosides, trimethoprim/ sulfamethoxazole
50/M
 BAS
 58
 Tracheobronchitis
 May 19
 Y
 COVID-19
 Carbapenems, ceftazidime, amikacin
52/M
 BAS
 37
 Tracheobronchitis
 May 20
 N
 COVID-19
 Carbapenems, ceftazidime, amikacin
56/M
 BAS
 43
 Ventilator-associated pneumonia
 May 22
 Y
 COVID-19
 Amikacin
58/F
 BAS
 80
 Tracheobronchitis
 May 29
 N
 COVID-19
 Amikacin
58/M
 BAS
 30
 Isolation
 Jul 7
 Y
 Fever
 Piperacillin/tazobactam, linezolid
37/F
 BAS
 51
 Isolation
 Aug 20
 Y
 COVID-19
 Piperacillin/tazobactam, linezolid
32/M
 BAS
 93
 Tracheobronchitis
 Sep 18
 Y
 COVID-19
 Piperacillin/tazobactam, linezolid
74/M
 BAS
 27
 Tracheobronchitis
 Sep 28
 Y
 Epileptic seizures
 Piperacillin/tazobactam, linezolid
61/M
 BAS
 27
 Ventilator-associated pneumonia
 Oct 27
 N
 Septic shock
 Piperacillin/tazobactam, linezolid, vancomycin,
73/M BAS 15 Ventilator-associated pneumonia Dec 30 N COVID-19 Piperacillin/tazobactam, linezolid, levofloxacin

*BAS, bronchoaspiration; ICU, intensive care unit. †Isolation means that no other clinical pathology was reported by the responsible physician in the ICU. Therefore, E. miricola identification was considered as asymptomatic colonization. ‡Antibiograms were compatible with the same agent, but development of new resistances was identified during the 9-mo outbreak. Trimethoprim/sulfamethoxazole showed the best antibiogram sensitivity: 10 patients showed sensitivity, 4 intermediate sensitivity, and only 1 showed resistance. Sensitivity to levofloxacin was observed for 7 (46.7%) patients; 4 more showed intermediate sensitivity.

Main Article

Page created: February 23, 2024
Page updated: March 21, 2024
Page reviewed: March 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external